Clinical Trial Update: A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated RO5313534 as an add-on to donepezil in patients with mild to moderate Alzheimer's disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Donepezil (donepezil)
• RO5313534

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED